Compare DAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAL | INSM |
|---|---|---|
| Founded | 1924 | 1988 |
| Country | United States | United States |
| Employees | 78400 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2B | 35.2B |
| IPO Year | 2004 | 2000 |
| Metric | DAL | INSM |
|---|---|---|
| Price | $68.14 | $155.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 23 |
| Target Price | $79.06 | ★ $191.09 |
| AVG Volume (30 Days) | ★ 7.6M | 2.1M |
| Earning Date | 04-14-2026 | 05-21-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 43.71 | N/A |
| EPS | ★ 7.66 | N/A |
| Revenue | ★ $41,244,000,000.00 | N/A |
| Revenue This Year | N/A | $130.70 |
| Revenue Next Year | $5.64 | $74.05 |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.74 | $60.40 |
| 52 Week High | $76.39 | $212.75 |
| Indicator | DAL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 45.50 |
| Support Level | $68.50 | $139.81 |
| Resistance Level | $72.75 | $166.84 |
| Average True Range (ATR) | 3.03 | 6.52 |
| MACD | -0.42 | 1.84 |
| Stochastic Oscillator | 23.08 | 45.07 |
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.